0
USD
U.S. (TOLL FREE)
+1 (425) 388-2538
Automative

0
U.S. (TOLL FREE)
+1 (425) 388-2538

Wet Macular Degeneration - Epidemiology Forecast to 2028

Published Date: March 2019
|
Report Code: DELV-Epid-218
Home | Category |Health |Vision Care
Wet Macular Degeneration Epidemiology Forecast to 2028

Wet Macular Degeneration - Epidemiology Forecast to 2028

Code: DELV-Epid-218
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Wet Macular Degeneration - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Wet Macular Degeneration epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Wet Macular Degeneration Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Wet Macular Degeneration in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Wet Macular Degeneration outlook. It also includes the explanation of changing trends of epidemiology outlining the Wet Macular Degeneration scenario.

Wet Macular Degeneration Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Wet Macular Degeneration thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Wet Macular Degeneration explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Wet Macular Degeneration Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Wet Macular Degeneration

Key assessments
• Patient Segmentation in Wet Macular Degeneration
• Wet Macular Degeneration Risk & Burden
• Factors driving growth in a specific Wet Macular Degeneration patient population

1. Report Introduction
2. Wet Macular Degeneration Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Wet Macular Degeneration in 2016
2.2. Patient Share Distribution of Wet Macular Degeneration in 2028
3. Disease Background and Overview: Wet Macular Degeneration
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Wet Macular Degeneration in 7MM
4.3. Total Prevalent/ Incident Patient Population of Wet Macular Degeneration in 7MM – By Countries
5. Epidemiology of Wet Macular Degeneration by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.1.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.1.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.1.5. Diagnosed Cases of the Wet Macular Degeneration
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.4.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.4.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.4.5. Diagnosed Cases of the Wet Macular Degeneration
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.5.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.5.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.5.5. Diagnosed Cases of the Wet Macular Degeneration
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.6.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.6.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.6.5. Diagnosed Cases of the Wet Macular Degeneration
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.7.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.7.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.7.5. Diagnosed Cases of the Wet Macular Degeneration
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.8.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.8.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.8.5. Diagnosed Cases of the Wet Macular Degeneration
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.9.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.9.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.9.5. Diagnosed Cases of the Wet Macular Degeneration
6. Unmet Needs of the Wet Macular Degeneration
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

LIST OF TABLES :

Table 1: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM
Table 2: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Wet Macular Degeneration in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Wet Macular Degeneration in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Wet Macular Degeneration in United States (2016-2028)*
Table 6: Diagnosed Cases of the Wet Macular Degeneration in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Wet Macular Degeneration in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Wet Macular Degeneration in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Wet Macular Degeneration in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Wet Macular Degeneration in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Wet Macular Degeneration in France (2016-2028)
Table 12: Sub-Type Specific cases of the Wet Macular Degeneration in France (2016-2028) *
Table 13: Sex- Specific Cases of the Wet Macular Degeneration in France (2016-2028) *
Table 14: Diagnosed Cases of the Wet Macular Degeneration in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Wet Macular Degeneration in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Wet Macular Degeneration in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Wet Macular Degeneration in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Wet Macular Degeneration in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Wet Macular Degeneration in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Wet Macular Degeneration in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Wet Macular Degeneration in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Wet Macular Degeneration in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Wet Macular Degeneration in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Wet Macular Degeneration in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Wet Macular Degeneration in UK (2016-2028) *
Table 26: Diagnosed Cases of the Wet Macular Degeneration in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Wet Macular Degeneration in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Wet Macular Degeneration in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Wet Macular Degeneration in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Wet Macular Degeneration in Japan (2016-2028)

LIST OF FIGURES :

Figure 1: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM
Figure 2: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Wet Macular Degeneration in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Wet Macular Degeneration in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Wet Macular Degeneration in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Wet Macular Degeneration in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Wet Macular Degeneration in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Wet Macular Degeneration in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Wet Macular Degeneration in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Wet Macular Degeneration in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Wet Macular Degeneration in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Wet Macular Degeneration in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Wet Macular Degeneration in France (2016-2028) *
Figure 14: Diagnosed Cases of the Wet Macular Degeneration in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Wet Macular Degeneration in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Wet Macular Degeneration in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Wet Macular Degeneration in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Wet Macular Degeneration in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Wet Macular Degeneration in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Wet Macular Degeneration in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Wet Macular Degeneration in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Wet Macular Degeneration in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Wet Macular Degeneration in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Wet Macular Degeneration in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Wet Macular Degeneration in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Wet Macular Degeneration in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Wet Macular Degeneration in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Wet Macular Degeneration in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Wet Macular Degeneration in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Wet Macular Degeneration in Japan (2016-2028)

DelveInsight's "Wet Macular Degeneration - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Wet Macular Degeneration epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Wet Macular Degeneration Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Wet Macular Degeneration in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Wet Macular Degeneration outlook. It also includes the explanation of changing trends of epidemiology outlining the Wet Macular Degeneration scenario.

Wet Macular Degeneration Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Wet Macular Degeneration thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Wet Macular Degeneration explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Wet Macular Degeneration Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Wet Macular Degeneration

Key assessments
• Patient Segmentation in Wet Macular Degeneration
• Wet Macular Degeneration Risk & Burden
• Factors driving growth in a specific Wet Macular Degeneration patient population

Read More

1. Report Introduction
2. Wet Macular Degeneration Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Wet Macular Degeneration in 2016
2.2. Patient Share Distribution of Wet Macular Degeneration in 2028
3. Disease Background and Overview: Wet Macular Degeneration
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Wet Macular Degeneration in 7MM
4.3. Total Prevalent/ Incident Patient Population of Wet Macular Degeneration in 7MM – By Countries
5. Epidemiology of Wet Macular Degeneration by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.1.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.1.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.1.5. Diagnosed Cases of the Wet Macular Degeneration
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.4.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.4.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.4.5. Diagnosed Cases of the Wet Macular Degeneration
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.5.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.5.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.5.5. Diagnosed Cases of the Wet Macular Degeneration
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.6.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.6.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.6.5. Diagnosed Cases of the Wet Macular Degeneration
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.7.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.7.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.7.5. Diagnosed Cases of the Wet Macular Degeneration
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.8.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.8.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.8.5. Diagnosed Cases of the Wet Macular Degeneration
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Wet Macular Degeneration
5.9.3. Sub-Type Specific cases of the Wet Macular Degeneration *
5.9.4. Sex- Specific Cases of the Wet Macular Degeneration *
5.9.5. Diagnosed Cases of the Wet Macular Degeneration
6. Unmet Needs of the Wet Macular Degeneration
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

Read More

LIST OF TABLES :

Table 1: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM
Table 2: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Wet Macular Degeneration in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Wet Macular Degeneration in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Wet Macular Degeneration in United States (2016-2028)*
Table 6: Diagnosed Cases of the Wet Macular Degeneration in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Wet Macular Degeneration in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Wet Macular Degeneration in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Wet Macular Degeneration in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Wet Macular Degeneration in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Wet Macular Degeneration in France (2016-2028)
Table 12: Sub-Type Specific cases of the Wet Macular Degeneration in France (2016-2028) *
Table 13: Sex- Specific Cases of the Wet Macular Degeneration in France (2016-2028) *
Table 14: Diagnosed Cases of the Wet Macular Degeneration in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Wet Macular Degeneration in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Wet Macular Degeneration in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Wet Macular Degeneration in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Wet Macular Degeneration in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Wet Macular Degeneration in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Wet Macular Degeneration in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Wet Macular Degeneration in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Wet Macular Degeneration in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Wet Macular Degeneration in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Wet Macular Degeneration in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Wet Macular Degeneration in UK (2016-2028) *
Table 26: Diagnosed Cases of the Wet Macular Degeneration in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Wet Macular Degeneration in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Wet Macular Degeneration in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Wet Macular Degeneration in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Wet Macular Degeneration in Japan (2016-2028)

LIST OF FIGURES :

Figure 1: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM
Figure 2: Total Prevalent/Incident Cases of the Wet Macular Degeneration in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Wet Macular Degeneration in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Wet Macular Degeneration in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Wet Macular Degeneration in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Wet Macular Degeneration in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Wet Macular Degeneration in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Wet Macular Degeneration in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Wet Macular Degeneration in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Wet Macular Degeneration in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Wet Macular Degeneration in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Wet Macular Degeneration in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Wet Macular Degeneration in France (2016-2028) *
Figure 14: Diagnosed Cases of the Wet Macular Degeneration in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Wet Macular Degeneration in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Wet Macular Degeneration in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Wet Macular Degeneration in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Wet Macular Degeneration in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Wet Macular Degeneration in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Wet Macular Degeneration in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Wet Macular Degeneration in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Wet Macular Degeneration in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Wet Macular Degeneration in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Wet Macular Degeneration in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Wet Macular Degeneration in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Wet Macular Degeneration in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Wet Macular Degeneration in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Wet Macular Degeneration in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Wet Macular Degeneration in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Wet Macular Degeneration in Japan (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)

RELATED REPORTS

Eye Drops and Lubricants Market by Type Antibiotics Hormones Artificial Tears and Others and Application Eye Diseases Eye Care and Others Global Opportunity Analysis and Industry Forecast 2018 2025
Eye Drops and Lubricants Market by Type Antibiotics Hormones Artificial Tears and Others and Application Eye Diseases Eye Care and Others Global Opportunity Analysis and Industry Forecast 2018 2025

Eye Drops and Lubricants Market by Type (Antibiotics, Hormones, Artificial Tears, and Others) and Application (Eye Diseases, Eye Care, and Others): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

120 Pages
Type: Report
Code: ALLI-Auto-2I344
Wed Nov 20 00:00:00 UTC 2019

Add to Cart

Ophthalmic Viscoelastic Devices OVD Market by Product Type Cohesive Ophthalmic Viscoelastic and Dispersive Ophthalmic Viscoelastic Application Cataract Surgery Glaucoma Surgery Corneal Transplant and Vitreoretinal Surgery and End User Hospital Ophthalmology Clinics and Others Global Opportunity Analysis and Industry Forecast 2019 2026
Ophthalmic Viscoelastic Devices OVD Market by Product Type Cohesive Ophthalmic Viscoelastic and Dispersive Ophthalmic Viscoelastic Application Cataract Surgery Glaucoma Surgery Corneal Transplant and Vitreoretinal Surgery and End User Hospital Ophthalmology Clinics and Others Global Opportunity Analysis and Industry Forecast 2019 2026

Ophthalmic Viscoelastic Devices (OVD) Market by Product Type (Cohesive Ophthalmic Viscoelastic, and Dispersive Ophthalmic Viscoelastic), Application (Cataract Surgery, Glaucoma Surgery, Corneal Transplant and Vitreoretinal Surgery), and End User (Hospital, Ophthalmology Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

120 Pages
Type: Report
Code: ALLI-Auto-0X357
Wed Nov 20 00:00:00 UTC 2019

Add to Cart

Eye Tracking Market by Type Head Mounted Eye Tracker and Remote Eye Tracker Application Assistive Communication Academic Research Consumer Behavior Research and Usability Testing and Industry Vertical Retail Automotive Healthcare Military Aerospace and Others Global Opportunity Analysis and Industry Forecast 2018 2024
Eye Tracking Market by Type Head Mounted Eye Tracker and Remote Eye Tracker Application Assistive Communication Academic Research Consumer Behavior Research and Usability Testing and Industry Vertical Retail Automotive Healthcare Military Aerospace and Others Global Opportunity Analysis and Industry Forecast 2018 2024

Eye Tracking Market by Type (Head-Mounted Eye Tracker and Remote Eye Tracker), Application (Assistive Communication, Academic Research, Consumer Behavior Research, and Usability Testing), and Industry Vertical (Retail, Automotive, Healthcare, Military & Aerospace, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2024

120 Pages
Type: Report
Code: ALLI-Auto-2G237
Tue Nov 19 00:00:00 UTC 2019

Add to Cart

Ophthalmic Drugs Market by Indication Dry Eye Glaucoma Infection Inflammation Allergy Retinal Disorders and Others Type Prescription Drugs and Over the Counter Drugs Dosage Form Liquid Ophthalmic Drug Forms Solid Ophthalmic Drug Forms Semisolid Ophthalmic Drug Forms Multicompartment Drug Delivery Systems and Other Ophthalmic Drug Forms Technology Biologics Cell Therapy Gene Therapy Drug Delivery Small Molecule and Others Distribution Channel Hospital Pharmacies Drug Stores Online Pharmacies and Others and Therapeutic Class Anti glaucoma Anti infection Anti inflammatory and Anti allergy Global Opportunity Analysis and Industry Forecast 2017 2023
Ophthalmic Drugs Market by Indication Dry Eye Glaucoma Infection Inflammation Allergy Retinal Disorders and Others Type Prescription Drugs and Over the Counter Drugs Dosage Form Liquid Ophthalmic Drug Forms Solid Ophthalmic Drug Forms Semisolid Ophthalmic Drug Forms Multicompartment Drug Delivery Systems and Other Ophthalmic Drug Forms Technology Biologics Cell Therapy Gene Therapy Drug Delivery Small Molecule and Others Distribution Channel Hospital Pharmacies Drug Stores Online Pharmacies and Others and Therapeutic Class Anti glaucoma Anti infection Anti inflammatory and Anti allergy Global Opportunity Analysis and Industry Forecast 2017 2023

Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs, and Over-the-Counter Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, and Others), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, and Others), and Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, and Anti-allergy) - Global Opportunity Analysis and Industry Forecast, 2017-2023

120 Pages
Type: Report
Code: ALLI-Auto-0D200
Tue Nov 19 00:00:00 UTC 2019

Add to Cart

0 Items
X
No items in the cart.
$0.0